105 related articles for article (PubMed ID: 35131874)
1. Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma.
Spiliopoulou P; Spear S; Mirza H; Garner I; McGarry L; Grundland-Freile F; Cheng Z; Ennis DP; Iyer N; McNamara S; Natoli M; Mason S; Blyth K; Adams PD; Roxburgh P; Fuchter MJ; Brown B; McNeish IA
Mol Cancer Ther; 2022 Apr; 21(4):522-534. PubMed ID: 35131874
[TBL] [Abstract][Full Text] [Related]
2. Elevated GALNT10 expression identifies immunosuppressive microenvironment and dismal prognosis of patients with high grade serous ovarian cancer.
Zhang G; Lu J; Yang M; Wang Y; Liu H; Xu C
Cancer Immunol Immunother; 2020 Feb; 69(2):175-187. PubMed ID: 31853576
[TBL] [Abstract][Full Text] [Related]
3. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.
Karakashev S; Zhu H; Wu S; Yokoyama Y; Bitler BG; Park PH; Lee JH; Kossenkov AV; Gaonkar KS; Yan H; Drapkin R; Conejo-Garcia JR; Speicher DW; Ordog T; Zhang R
Nat Commun; 2018 Feb; 9(1):631. PubMed ID: 29434212
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of prexasertib monotherapy in recurrent
Lampert EJ; Cimino-Mathews A; Lee JS; Nair J; Lee MJ; Yuno A; An D; Trepel JB; Ruppin E; Lee JM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32709712
[TBL] [Abstract][Full Text] [Related]
5. Improved overall survival in patients with high-grade serous ovarian cancer is associated with CD16a+ immunologic neighborhoods containing NK cells, T cells and macrophages.
Nersesian S; Arseneau RJ; Mejia JP; Lee SN; Westhaver LP; Griffiths NW; Grantham SR; Meunier L; Communal L; Mukherjee A; Mes-Masson AM; Arnason T; Nelson BH; Boudreau JE
Front Immunol; 2023; 14():1307873. PubMed ID: 38318505
[TBL] [Abstract][Full Text] [Related]
6. EZH2 Contributes to Anoikis Resistance and Promotes Epithelial Ovarian Cancer Peritoneal Metastasis by Regulating m6A.
Wang SH; Liu L; Bao KY; Zhang YF; Wang WW; Du S; Jia NE; Suo S; Cai J; Guo JF; Lv G
Curr Med Sci; 2023 Aug; 43(4):794-802. PubMed ID: 37498408
[TBL] [Abstract][Full Text] [Related]
7. Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth.
Wilkinson AN; Chen R; Coleborn E; Neilson T; Le K; Bhavsar C; Wang Y; Atluri S; Irgam G; Wong K; Yang D; Steptoe R; Wu SY
Cancer Immunol Immunother; 2024 Mar; 73(5):80. PubMed ID: 38554167
[TBL] [Abstract][Full Text] [Related]
8. Harnessing Antitumor Immunity in Ovarian Cancer.
Kurnit KC; Odunsi K
Cold Spring Harb Perspect Med; 2024 Apr; ():. PubMed ID: 38621830
[TBL] [Abstract][Full Text] [Related]
9. The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
Smith P; Bradley T; Gavarró LM; Goranova T; Ennis DP; Mirza HB; De Silva D; Piskorz AM; Sauer CM; Al-Khalidi S; Funingana IG; Reinius MAV; Giannone G; Lewsley LA; Stobo J; McQueen J; Bryson G; Eldridge M; ; Macintyre G; Markowetz F; Brenton JD; McNeish IA
Nat Commun; 2023 Jul; 14(1):4387. PubMed ID: 37474499
[TBL] [Abstract][Full Text] [Related]
10. First-in-Class Dual EZH2-HSP90 Inhibitor Eliciting Striking Antiglioblastoma Activity
Sharma S; Wang SA; Yang WB; Lin HY; Lai MJ; Chen HC; Kao TY; Hsu FL; Nepali K; Hsu TI; Liou JP
J Med Chem; 2024 Feb; 67(4):2963-2985. PubMed ID: 38285511
[TBL] [Abstract][Full Text] [Related]
11. Determinants of DNMT2/TRDMT1 preference for substrates tRNA and DNA during the evolution.
Li H; Zhu D; Yang Y; Ma Y; Chen Y; Xue P; Chen J; Qin M; Xu D; Cai C; Cheng H
RNA Biol; 2023 Jan; 20(1):875-892. PubMed ID: 37966982
[TBL] [Abstract][Full Text] [Related]
12. Distinct functions of EHMT1 and EHMT2 in cancer chemotherapy and immunotherapy.
Kang Z; Fu P; Ma H; Li T; Lu K; Liu J; Ginjala V; Romanienko P; Feng Z; Guan M; Ganesan S; Xia B
bioRxiv; 2023 Oct; ():. PubMed ID: 37873068
[TBL] [Abstract][Full Text] [Related]
13. An epigenetic hypothesis for ovarian cancer prevention by oral contraceptive pill use.
Avramenko AS; Flanagan JM
Clin Epigenetics; 2023 Oct; 15(1):165. PubMed ID: 37853473
[TBL] [Abstract][Full Text] [Related]
14. What nature has to offer: Opportunities for immuno-oncology.
Kousar R; Lin CH; Patrick B; He M; Wu DC; Li XG
J Food Drug Anal; 2023 Jun; 31(2):212-231. PubMed ID: 37335163
[TBL] [Abstract][Full Text] [Related]
15. In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer.
Quintela M; James DW; Garcia J; Edwards K; Margarit L; Das N; Lutchman-Singh K; Beynon AL; Rioja I; Prinjha RK; Harker NR; Gonzalez D; Steven Conlan R; Francis LW
Br J Cancer; 2023 Jul; 129(1):163-174. PubMed ID: 37120667
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells.
Sbirkov Y; Schenk T; Kwok C; Stengel S; Brown R; Brown G; Chesler L; Zelent A; Fuchter MJ; Petrie K
Front Cell Dev Biol; 2023; 11():1076458. PubMed ID: 37035245
[TBL] [Abstract][Full Text] [Related]
17. Novel insights into histone lysine methyltransferases in cancer therapy: From epigenetic regulation to selective drugs.
Liao Q; Yang J; Ge S; Chai P; Fan J; Jia R
J Pharm Anal; 2023 Feb; 13(2):127-141. PubMed ID: 36908859
[TBL] [Abstract][Full Text] [Related]
18. Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer.
Thng DKH; Hooi L; Toh CCM; Lim JJ; Rajagopalan D; Syariff IQC; Tan ZM; Rashid MBMA; Zhou L; Kow AWC; Bonney GK; Goh BKP; Kam JH; Jha S; Dan YY; Chow PKH; Toh TB; Chow EK
Mol Oncol; 2023 Nov; 17(11):2275-2294. PubMed ID: 36896891
[TBL] [Abstract][Full Text] [Related]
19. Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models.
Nguyen LL; Watson ZL; Ortega R; Woodruff ER; Jordan KR; Iwanaga R; Yamamoto TM; Bailey CA; Jeong AD; Guntupalli SR; Behbakht K; Gbaja V; Arnoult N; Chuong EB; Bitler BG
bioRxiv; 2023 Feb; ():. PubMed ID: 36865165
[TBL] [Abstract][Full Text] [Related]
20. The role of histone methylase and demethylase in antitumor immunity: A new direction for immunotherapy.
Zhang Y; Chen J; Liu H; Mi R; Huang R; Li X; Fan F; Xie X; Ding J
Front Immunol; 2022; 13():1099892. PubMed ID: 36713412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
